China's Fosun to end BioNTech's COVID-19 vaccine trial, seek approval for another | Reuters
Description
BioNTech's Chinese partner Shanghai Fosun Pharmaceutical Group does not plan to run further clinical trials of the German firm's coronavirus vaccine candidate that has completed early-stage trials in China, an executive said.